8-K: Kairos Pharma Unveils Promising KROS101 Cancer Immunotherapy Data at ASCO 2025

Kairos Pharma, Ltd. announced positive new data on its investigational small molecule GITR ligand agonist KROS101, highlighting its potential as a cancer immunotherapy at the ASCO 2025 Annual Meeting.

Summary

• Kairos Pharma, Ltd. (NYSE American: KAPA) presented new data on its investigational small molecule GITR ligand agonist KROS101 at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
• The presentation, titled "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," demonstrated KROS101's capability as a potent GITR ligand agonist with dual mechanisms of action.
• The study found that KROS101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, boosting cytokine production and tumor cancer cell killing.
• Additionally, KROS101 reduced T reg-mediated suppression by decreasing T reg populations, thereby reversing immune system suppression and enhancing effector T cell activity.
• The study also showed KROS101 to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity, and preventing T cell exhaustion.
• Kairos Pharma's lead candidate, ENV105, an antibody targeting CD105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer.

Sentiment

Score: 8

Explanation: The document presents highly positive preclinical/early-stage clinical data for KROS101, highlighting its dual mechanism of action and superiority over a previous compound. Management comments are optimistic about its potential in a high-need market. The news is about promising scientific progress in a key therapeutic area.

Positives

• KROS101 demonstrated capability as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action.
• The study showed KROS101 enhanced T cell function by promoting proliferation and increasing cytotoxicity.
• KROS101 boosted cytokine production and tumor cancer cell killing.
• KROS101 reduced T reg-mediated suppression by reducing T reg populations, reversing immune system suppression and enhancing effector T cell activity.
• KROS101 was found to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity, and preventing T cell exhaustion.
• The results strongly support continued study of KROS101 as a cancer immunotherapy.
• KROS101's dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions.

Risks

• Underlying assumptions proving inaccurate, or known or unknown risks or uncertainties materializing, could cause actual results to vary materially from the expectations and projections.
• Challenges and uncertainties inherent in product research and development.
• Uncertainty regarding future commercial success.
• Actual events and results may differ materially and are subject to risks, uncertainties, and assumptions described in Kairos Pharma's Annual Report on Form 10-K and other SEC filings.

Future Outlook

Kairos Pharma continues to believe that KROS101 has the potential to help optimize cancer treatment and looks forward to discussing these findings with the medical and scientific communities while providing additional progress updates. The company's forward-looking statements relate to expectations regarding the success and/or completion of Phase 1 and Phase 2 clinical trials, success in completing newly initiated clinical trials, commencing new trials, and obtaining regulatory approval following the conclusion of such trials.

Management Comments

• "These results strongly support continued study of KROS101 as a cancer immunotherapy, as they show strong activity in boosting the immune system while targeting and killing tumor cells." Dr. John Yu, Kairos CEO
• "Its dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions." Dr. John Yu, Kairos CEO
• "We continue to believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing these findings with the medical and scientific communities while providing additional progress updates as appropriate." Dr. John Yu, Kairos CEO

Industry Context

The announcement positions KROS101 as a promising new solution in the cancer immunotherapy market, which is described as being "in desperate need of new solutions." This suggests Kairos Pharma aims to address significant unmet medical needs with its dual-mechanism approach, potentially offering an advancement over previous therapies like anti-GITR antibody TRX518.

Comparison to Industry Standards

• KROS101 was shown to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity, and preventing T cell exhaustion. TRX518 was previously in clinical trials.

Stakeholder Impact

• Shareholders: Positive news regarding a key pipeline candidate (KROS101) could increase investor confidence and potentially lead to share price appreciation.
• Medical/Scientific Community: The data presentation at ASCO and future discussions aim to inform and engage these communities, potentially leading to collaborations or increased interest in KROS101.
• Patients: The development of KROS101 and ENV105 aims to address significant unmet medical needs in cancer treatment, offering potential new therapeutic options.

Next Steps

• Continued study of KROS101 as a cancer immunotherapy.
• Discussion of findings with the medical and scientific communities.
• Providing additional progress updates as appropriate.
• Completion of Phase 1 and Phase 2 clinical trials for ENV105.
• Commencement of new clinical trials.
• Obtaining regulatory approval following the conclusion of trials.

Key Dates

Recommendation

Keywords

Kairos Pharma, KAPA, KROS101, GITR ligand agonist, cancer immunotherapy, ASCO 2025, oncology, biopharmaceutical, clinical stage, T cell function, tumor cell killing, immune response, TRX518, ENV105, CD105, prostate cancer, lung cancer